Related Experiment Video
Updated: Jun 28, 2025
11:07
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
7.8K
Transperineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer
Gugliemo Manenti1, Tommaso Perretta1, Marco Nezzo1
1Diagnostic Imaging and Interventional Radiology Policlinico Tor Vergata, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
Cancers
|April 13, 2024
Summary
Focal laser ablation (FLA) offers a safe and effective treatment for low-intermediate-risk prostate cancer, showing significant PSA reduction and high tumor eradication rates over three years.
Area of Science:
- Urology
- Oncology
- Minimally Invasive Surgery
Background:
- Pilot study evaluating focal laser ablation (FLA) for low-intermediate-risk prostate cancer.
- Focus on short-term efficacy and safety of treating the index lesion.
- Utilizes ClinicalTrials.gov ID NCT04045756 for tracking.
Purpose of the Study:
- Assess the short-term efficacy of FLA in treating the primary tumor of prostate cancer.
- Evaluate the safety profile of FLA in a day hospital setting.
- Determine the impact of FLA on patient quality of life, including sexual and urinary function.
Main Methods:
- Interventional study with 40 patients (age 46-86) diagnosed with organ-confined, low-intermediate-risk prostate cancer.
- FLA performed under MRI/ultrasound guidance with local anesthesia.
- Regular assessments included PSA levels, IIEF-5, IPSS, MRI scans, and biopsies at 36 months.
Main Results:
- Mean PSA reduction of 60% observed at 36 months.
- 80% of MRI scans showed no evidence of residual or recurrent cancer in the treated area.
- Biopsies at 36 months confirmed no malignant findings in 20 patients; no decline in sexual or urinary function.
Conclusions:
- FLA is a safe, feasible, and effective treatment option for the index lesion in low-intermediate-risk prostate cancer.
- High rates of tumor eradication were achieved with FLA.
- The procedure demonstrated preservation of patient quality of life regarding sexual and urinary function.
